Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2354MR)

This product GTTS-WQ2354MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ2354MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5113MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Campath-1H
GTTS-WQ14849MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ12037MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ3681MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ14000MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ11120MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ5819MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ4595MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW